Literature DB >> 3899674

Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism.

A Ulmann, C Bertagna, A Le Go, J M Husson, A Tache, P Sassano, J Menard, P Corvol.   

Abstract

The antimineralocorticoid effect of a single dose of RU 28318, has been assessed in healthy men with exogenous or endogenous hypermineralocorticism. For exogenous hypermineralocorticism induced by ingestion of 9 alpha-fluorohydrocortisone (9 alpha-FHC) and aldosterone infusion, RU 28318 100 mg (9 alpha-FHC ingestion) or 200 mg (aldosterone infusion) was administered, and its effect compared with identical doses of spironolactone or a placebo. For endogenous hypermineralocorticism induced by ingestion of furosemide, RU 28318 100 and 300 mg was tested in comparison with 100 mg spironolactone or placebo. In all 3 studies, both RU 28318 and spironolactone significantly raised the urinary Na/K ratio when compared to placebo administration. No significant difference was apparent between RU 28318 and spironolactone. Thus, a single dose of RU 28318 in man has an antimineralocorticoid effect identical to those produced by the identical molar dose of spironolactone. In addition, the results show that furosemide-induced hyperaldosteronism constitutes a simple and reproducible test for assessing the antimineralocorticoid effect of a drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899674     DOI: 10.1007/bf00544063

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  The effects of glucose and insulin on renal electrolyte transport.

Authors:  R A DeFronzo; M Goldberg; Z S Agus
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

Review 2.  Aldosterone: current concepts.

Authors:  D J Morris; R P Davis
Journal:  Metabolism       Date:  1974-05       Impact factor: 8.694

3.  Mineralocorticoid-induced blood pressure, electrolyte, and hormone changes, and reversal with spironolactone, in healthy men.

Authors:  M G Nicholls; L E Ramsay; K Boddy; R Fraser; J J Morton; J I Robertson
Journal:  Metabolism       Date:  1979-05       Impact factor: 8.694

4.  Antihypertensive effect of spironolactone in essential, renal and mineralocorticoid hypertension.

Authors:  F Mantero; D Armanini; S Urbani
Journal:  Clin Sci Mol Med Suppl       Date:  1973-08

5.  Orally active mineralocorticoid agonists and antagonists: delta 1-derivatives of aldosterone and 18-deoxyaldosterone.

Authors:  W R Adam; J W Funder; S Ulick
Journal:  Endocrinology       Date:  1981-02       Impact factor: 4.736

6.  The effect of the antimineralocorticoid RU 28318 on aldosterone biosynthesis in vitro.

Authors:  I Perroteau; P Netchitailo; C Delarue; F Leboulenger; D Philibert; R Deraedt; H Vaudry
Journal:  J Steroid Biochem       Date:  1984-04       Impact factor: 4.292

Review 7.  Evaluation of aldosterone antagonists in healthy man.

Authors:  G T McInnes; J R Shelton; L E Ramsay
Journal:  Methods Find Exp Clin Pharmacol       Date:  1982

8.  Improved method for comparative evaluation of aldosterone antagonists in healthy man.

Authors:  J Casals-Stenzel; J Schmalbach; W Losert
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

9.  Spironolactone and potassium canrenoate in normal man.

Authors:  L Ramsay; J Shelton; I Harrison; M Tidd; M Asbury
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

10.  Spironolactone and endocrine dysfunction.

Authors: 
Journal:  Ann Intern Med       Date:  1976-11       Impact factor: 25.391

View more
  5 in total

Review 1.  Corticosteroid receptor antagonists: a current perspective.

Authors:  W Sutanto; E R de Kloet
Journal:  Pharm World Sci       Date:  1995-03-24

2.  Antagonism in the human mineralocorticoid receptor.

Authors:  J Fagart; J M Wurtz; A Souque; C Hellal-Levy; D Moras; M E Rafestin-Oblin
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

3.  Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure.

Authors:  B Couette; J Fagart; S Jalaguier; M Lombes; A Souque; M E Rafestin-Oblin
Journal:  Biochem J       Date:  1996-04-15       Impact factor: 3.857

Review 4.  30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.

Authors:  Peter Kolkhof; Lars Bärfacker
Journal:  J Endocrinol       Date:  2017-07       Impact factor: 4.286

Review 5.  GABA Signaling and Neuroactive Steroids in Adrenal Medullary Chromaffin Cells.

Authors:  Keita Harada; Hidetada Matsuoka; Hiroaki Fujihara; Yoichi Ueta; Yuchio Yanagawa; Masumi Inoue
Journal:  Front Cell Neurosci       Date:  2016-04-18       Impact factor: 5.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.